Related Experiment Video
Updated: Nov 21, 2025

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome
Sharmila Raghunandan1,2, Cassandra D Josephson2,3, Hans Verkerke3
1Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, United States.
Insights
Most children with COVID-19 experience mild illness, but severe cases can cause acute respiratory distress syndrome (ARDS). Complement-mediated lung injury may play a role, as suggested by a case treated with convalescent plasma and eculizumab.
Area of Science:
- Pediatric critical care medicine
- Immunology
- Infectious diseases
Background:
- COVID-19 in children often presents as mild or asymptomatic illness.
- Critically ill children with COVID-19 may develop acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI).
- Lung function deterioration in COVID-19 is associated with microangiopathic and immune-mediated processes, potentially involving complement activation.
Observation:
- The role of complement-mediated acute lung injury is supported by animal models, human autopsy data, and therapeutic responses.
- A case of a child with severe COVID-19 treated with convalescent plasma and eculizumab is presented.
- Detailed evaluation of inflammatory pathways in this case is provided.
Findings:
- Complement inhibition may be a therapeutic target for severe COVID-19 ARDS.
- Understanding inflammatory pathways is crucial for managing critical illness in children.
- Convalescent plasma and eculizumab were used in a pediatric case of severe COVID-19.
Implications:
- This case highlights the potential role of complement in pediatric COVID-19 lung injury.
- Further research into complement-targeted therapies for severe COVID-19 in children is warranted.
- Insights into inflammatory pathways can inform treatment strategies for critical COVID-19.
Abstract:
Most children with COVID-19 have asymptomatic or mild illness. Those who become critically ill suffer from acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI). The rapid deterioration of lung function has been linked to microangiopathic and immune-mediated processes seen in the lungs of adult patients with COVID-19. The role of complement-mediated acute lung injury is supported by animal models of SARS-CoV, evaluation of lung tissue in those who died from COVID-19 and response of COVID-19 ARDS to complement inhibition. We present a summary of a child with COVID-19 disease treated with convalescent plasma and eculizumab and provide a detailed evaluation of the inflammatory pathways.
More Related Videos
Related Concept Videos
Complement System
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-III
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-IV

